Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment

Pharmacology and Therapeutics

Volumn 88, Issue 1, 2000, Pages 15-31

  Marín, Jesús ^a,b   Marín, Esperanza ^a   Gutierrez Iiguez M Angeles ^a   Avendao, Cristina ^a   Rodriguez Martinez M Angeles ^a,b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

agonists and antagonists; Angiotensin converting enzyme inhibitors; Ca2+ sensitizers; Congestive heart failure; Inotropic agents; Neuroendocrine mechanisms

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CALCIUM SENSITIZER; CANDOXATRIL; CARDIOVASCULAR AGENT; CYCLIC AMP; DIGITALIS LIKE FACTOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; IBOPAMINE; INOTROPIC AGENT; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ADAPTATION; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CHEMORECEPTOR; CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEART OUTPUT; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; VASCULAR ENDOTHELIUM;

ANIMAL; CARDIOVASCULAR AGENTS; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0033807478     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00076-0     Document Type: Review

References (183)

1. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure
2. Losartan improves the natriuretic response to ANF in rats with high-output heart failure
3. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy
4. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
5. Effect of antiplatelet agents on survival in patients with left ventricular systolic dysfunction
6. Pathogenesis of salt and water retention in the congestive heart failure syndrome. In P. A. Poole-Eilson, W. S. Colucci, B. M. Massie, K. Chatterjee, & A. J. Coats (Eds.)
7. Mechanisms and management of renal dysfunction in heart failure
8. Hemodynamic, hormonal and renal effects of atrial natriuretic peptide in untreated congestive heart failure
9. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease
10. Renal hemodynamics in congestive heart failure
11. The cellular basis of cardiotonic steroid action
12. Novel drugs and current therapeutic approaches in the treatment of heart failure
13. Isolated systolic hypertension in the elderly
14. Clinical pharmacology of loop diuretics
15. Why does the myocardium fail?; new insights from basic science
16. Heart rate variability in patients with mild to moderate heart failure; effects of neurohormonal modulation by digoxin and ibopamine
17. Flolan International Randomized Survival Trial (FIRST); final results
18. Ion transport systems sequenced
19. Is renal dose dopamine protective or therapeutic? Yes
20. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure
21. Heart failure therapy in evolution
22. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults
23. Prejunctional angiotensin II receptors; facilitation of norepinephrine release in the human forearm
24. Piretamide, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
25. Controlled trial of physical training in chronic heart failure; exercise performance, hemodynamics, ventilation, and autonomic function
26. Atrial natriuretic factor in normal subjects and heart failure patients
27. Current therapy of the failing heart
28. Current concepts in the treatment of congestive heart failure
29. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study
30. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
31. Newer drug therapy for congestive heart failure
32. The epidemiology of heart failure
33. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure; comparison with the renin-angiotensin system and the sympathetic nervous system
34. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
35. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure
36. Optimal treatment of heart failure in the elderly
37. Endothelium as a therapeutic target in heart failure
38. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure
39. Signalling pathways in failing human heart muscle cells
40. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat
41. Prostaglandins in severe congestive heart failure; relation to activation of the renin-angiotensin system and hyponatremia
42. Medical therapy can improve the biological properties of the chronically failing heart; a new era in the treatment of heart failure
43. Calcium channel blockers in heart failure
44. Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure
45. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition
46. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure
47. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure
48. Angiotensin modulation of vascular tone and adrenergic neurotransmission in cat femoral arteries
49. Multiplicity of cardiac glycoside receptors in the heart
50. Serum-free carnitine levels in children with heart failure
51. In search of the digitalis replacement
52. Urodilatin; a newly described member of the ANP family
53. The clinical potential of endothelin receptor antagonists in cardiovascular medicine
54. Hemodynamic effects of inhibitors of the renin-angiotensin system
55. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure; a substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
56. Plasma norepinephrine, plasma renin activity, and congestive heart failure; relations to survival and the effects of therapy in V-HeFT II
57. Ascorbate is an outstanding antioxidant in human blood plasma
58. Digoxin. A neurohormonal modulator in heart failure?
59. Na, K-ATPase in several tissues of the rat; tissue-specific expression of subunit mRNAs and enzyme activity
60. +-pump and its relevance in the treatment of heart failure
61. Renal response to indomethacin in ischemic or idiopathic dilated cardiomyopathy
62. Inhibiteurs de l'enzyme de conversion de l'angiotensine et antagonistes calciques. Leur place dans le treatment de l'insuffisance cardiaque du sujet age
63. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla; relation to adenylate cyclase activation
64. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure
65. Inappropriate use of digoxin in the elderly. How widespread is the problem and how can it be solved?
66. Mechanisms of action of calcium-sensitizing drugs
67. Congestive cardiac failure; central role of the arterial blood pressure
68. β-blocker use in systolic heart failure and dilated cardiomyopathy
69. Cardiac glycosides in the next millennium
70. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure
71. The role of β-blockers in left ventricular dysfunction and heart failure
72. The epidemiology of heart failure; the Framingham Study
73. Therapeutic potential of vitamin E against myocardial ischemic-reperfusion injury
74. Future management of high blood pressure
75. Interaction between atrial natriuretic peptide (ANP) and the renin angiotensin aldosterone system; endogenous antagonists
76. Autonomic nervous and behavioral factors in hypertension
77. The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure
78. Mechanisms and implications of endothelial dysfunction in congestive heart failure
79. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits
80. Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts
81. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
82. Long-term administration of atrial natriuretic peptide in patients with acute heart failure
83. Treatment of heart failure
84. Endothelium dependent vasodilation is attenuated in patients with heart failure
85. L-arginine increases exercise-induced vasodilatation of the forearm in patients with heart failure
86. Atrial and brain natriuretic peptides; a dual natriuretic peptide system potentially involved in circulatory homeostasis
87. Mechanism of action of the cardiac glycosides on the heart
88. Active transport and inotropic state in guinea pig left atrium
89. Brain 'ouabain' mediates sympathetic hyperactivity in congestive heart failure
90. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
91. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease
92. Physiological studies of the natriuretic peptide family
93. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure
94. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure
95. Carnitine and myocardial glucose metabolism
96. Angiotensin II on the evolution of experimental heart failure
97. Basic mechanisms in congestive heart failure; recognizing the role of proinflammatory cytokines
98. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure; a double-blind placebo-controlled, randomized crossover trial
99. Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure
100. Age-related changes in vascular responses; a review
101. Angiotensin-converting enzyme inhibitors and the role of nitric oxide and excitatory amino acids in improvement of cognition and memory
102. Vascular sodium pump and modulation of its activity by endothelium
103. Role of vascular nitric oxide in physiological and pathological conditions
104. Sympathetic dysregulation in heart failure; mechanisms and therapy
105. Heart failure 1997; a time to take stock
106. Calcium sensitizing agents in heart failure
107. Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure
108. Nonpeptide vasopressin antagonists; a new group of hormone blockers entering the scene
109. Recent advances in the drug treatment of heart failure
110. Significance of sodium pump isoforms in digitalis therapy
111. The natriuretic peptide family
112. Community management of heart failure
113. Ongoing and planned clinical trial in chronic heart failure and left ventricular dysfunction
114. Mechanisms and implications of autonomic nervous system dysfunction in heart failure
115. Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs (role changes in heart rate, atrial dimension, and cardiac tissue concentration)
116. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure
117. Response of large and small vessels to α and β adrenoceptor stimulation in heart failure; effect of angiotensin converting enzyme inhibition
118. Effects of a vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction
119. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANP degradation in patients with severe chronic heart failure
120. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
121. Acute effects of β-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure
122. Potent aquaretic agent; a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men
123. +-ATPase inhibition from digitalis inotropy
124. Long-term strategies in the management of heart failure; looking beyond ventricular function and symptoms
125. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency in severe chronic heart failure
126. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure
127. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors
128. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
129. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure
130. Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors
131. Cardiac effects of six actodigin (AY-22,241)-related semisynthetic glycosides
132. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure; effects of physical training
133. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure
134. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium
135. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In the Elderly study, ELITE)
136. Cardiac and arterial baroreceptor influences in release of vasopressin and renin during hemorrhage
137. Reductions in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy; preliminary observations
138. Randomized, double-blind, placebo-controlled trial of supplemental oral L-arginine in patients with heart failure
139. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive failure in the dog
140. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases
141. Inotropic agents for heart failure; what if digoxin increases mortality?
142. Toward the discovery of digitalis derivatives with inotropic selectivity
143. Effect of acetylsalicylic acid on renal function
144. Pharmacology of carvedilol; rationale for use in hypertension, coronary artery disease, and congestive heart failure
145. Effects of ACE inhibitors on circulating versus cardiac angiotensin in volume overload-induced cardiac hypertrophy in rats
146. Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure
147. Beneficial effects of amiodarone in heart failure; interaction with β-adrenoceptors rather than G proteins
148. Angiotensin II directly stimulates transport in rabbit proximal convoluted tubules
149. Studies on the digitalis receptor
150. 2+ exchanger protein levels in human heart failure
151. Characterisation of Na/K-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts
152. 3H) ouabain binding to some sympathetically innervated organs of the cat
153. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure
154. Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II
155. Oxidative stress and heart failure
156. Central nervous system mediators of vasopressin release
157. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?
158. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct
159. Multiple digitalis receptors. A molecular perspective
160. Effects of enalapril on mortality in severe congestive heart failure; results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
161. The effect of digoxin on mortality and morbidity in patients with heart failure
162. Study on propionyl-L-carnitine in chronic heart failure
163. Guidelines for the diagnosis of heart failure
164. The treatment of heart failure
165. Prevention on endothelial dysfunction in small and large arteries in a model of chronic heart failure; effect of angiotensin converting enzyme inhibition
166. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus
167. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure; results of the PROVED trial
168. Cardiovascular drug therapy. What is new? ACE-inhibitors
169. Current and newer approaches in the drug treatment of congestive heart failure
170. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure
171. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells; a potential link between the renin-angiotensin system and thrombosis
172. Epidemiology and risk of hypertension in the elderly; the Framingham study
173. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
174. Defective endothelium-mediated control of coronary circulation in conscious dog after heart failure
175. Nonpeptide angiotensin II receptor antagonists; the next generation in antihypertensive therapy
176. Kinins and cardioprotection
177. Pharmacology of renin inhibitors and their application to the treatment of hypertension
178. Reversing congestive heart failure with endothelin receptor antagonists
179. SB 21145, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant
180. Expression of alpha isoforms of the Na,K-ATPase in human heart
181. +-ATPase is associated with the sites of cardiac and neuromuscular impulse transmission
182. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure